1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,560 | 10,000 | 07:54 | |
| 9,660 | 9,940 | 07:36 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11. | Bioventus expects 2026 revenue of $590M-$595M while reaffirming adjusted EPS of $0.75-$0.79 | 2 | Seeking Alpha | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 02.11. | Bioventus Q3 2026 Earnings Call Transcript | 3 | Benzinga.com | ||
| 02.11. | Bioventus Non-GAAP EPS of $0.17 beats by $0.01, revenue of $142.4M misses by $7.12M | 2 | Seeking Alpha | ||
| 02.11. | Bioventus, Inc.: Bioventus Reports Third Quarter Financial Results | 3 | GlobeNewswire (USA) | ||
| 02.11. | Bioventus Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 02.11. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.10. | Bioventus, Inc.: Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026 | 1 | GlobeNewswire (USA) | ||
| 06.08. | Biotech Stocks At 52-Week Highs - Bioventus, Travere Therapeutics, Odyssey Therapeutics, Charles River Laboratories Climb With Q2 Results, Aclaris Therapeutics | 1.283 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 5, 2026, primarily driven by positive quarterly reports.Bioventus Inc. (BVS)Bioventus is a medical device... ► Artikel lesen | |
| 05.08. | Bioventus Inc. Q2 Profit Advances | 2 | RTTNews | ||
| 05.08. | Bioventus Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 05.08. | Bioventus Non-GAAP EPS of $0.22 in-line, revenue of $153.2M misses by $2.44M | 1 | Seeking Alpha | ||
| 05.08. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.08. | Bioventus, Inc.: Bioventus Reports Second Quarter Financial Results | 371 | GlobeNewswire (Europe) | Q2 reported revenue of $153.2 million increased 4%Q2 GAAP earnings of $0.47 per diluted share compared to the prior-year period earnings of $0.11 per diluted shareNon-GAAP earnings* of $0.22 per diluted... ► Artikel lesen | |
| 29.07. | Biotech Stocks At 52-Week Highs - Incyte Rises With Q2 Results, Pulse Biosciences, Shoulder Innovations, Bioventus, LB Pharmaceuticals | 1.003 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 28, 2026, driven by key catalysts including positive quarterly results.Incyte Corporation (INCY)Incyte is a... ► Artikel lesen | |
| 24.07. | Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect? | 1 | Zacks | ||
| 08.07. | Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know | 3 | Zacks | ||
| 07.07. | Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? | 1 | Zacks | ||
| 23.06. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | 790 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| 04.06. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Transcript: Bioventus Q1 2026 Earnings Conference Call | 1 | Benzinga.com |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,120 | +4,00 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,351 | +1,96 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,626 | -1,13 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| INFLARX | 1,070 | -4,21 % | InflaRx: 2027 im Blick - warum Izicopan jetzt an Gewicht gewinnt | ||
| INTELLIA THERAPEUTICS | 9,550 | 0,00 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| DEFENCE THERAPEUTICS | 0,188 | +8,05 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,000 | +3,36 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,800 | -2,05 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| CARDIOL THERAPEUTICS | 0,950 | +0,42 % | Milliardenchance Herztherapie: Cardiol Therapeutics, Kiniksa und Novo Nordisk | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Behandlung von entzündlichen Herzerkrankungen entwickelt sich aktuell zu einem der lukrativsten Segmente der Pharmabranche. Das bislang... ► Artikel lesen | |
| GERON | 0,884 | 0,00 % | Geron auf der Stifel Healthcare Conference 2026: RYTELO gewinnt an Dynamik | ||
| IBIO | 0,712 | +2,59 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update | ||
| ARBUTUS BIOPHARMA | 3,500 | -4,11 % | Arbutus Biopharma GAAP EPS of $0.30 beats by $0.32, revenue of $0.3M misses by $0.7M | ||
| IMMUNITYBIO | 5,580 | +1,64 % | ImmunityBio, Inc.: ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 | Senior leadership will discuss ImmunityBio's clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
ImmunityBio, Inc. (NASDAQ:... ► Artikel lesen | |
| IMMATICS | 5,840 | -0,68 % | Immatics Announces Third Quarter 2026 Financial Results and Business Update | Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) is on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 1,170 | 0,00 % | Cellectar Biosciences GAAP EPS of -$0.46 beats by $0.10 |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 9,760 Euro und damit -1,01 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.